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For this January’s issue ofNeurology: Neuroimmunology and Neuroinflammation (N2), the editors
have selected articles from this and other journals that they found interesting over the course of
2018. These articles are from different areas of the fields of neuroimmunology and neuro-
inflammation and are discussed in a brief commentary that we hope will inspire our readers to
further explore these topics.
The use of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of cancer, with
an increasing number of histologic tumor types being considered for these treatments.1 ICIs
target molecules such as cytotoxic T lymphocyte–associated antigen 4, programmed cell death
protein (PD1), and PD1 ligand that are expressed on activated immune cells (T cells, B cells,
natural killer cells, and some myeloid cells) and regulate inflammatory and autoimmune
responses through a negative feedback mechanism.2 Boosting the immune system with mono-
clonal antibodies against these molecules can result in serious immune-related adverse effects
(irAEs) that manifest with an extensive variety of symptoms affecting the peripheral or CNS.
Several mechanisms have been proposed for irAEs, including, among others, (1) exacerbation of
a preexisting immune disorder, such as multiple sclerosis (MS), during or after the initiation of
ICIs and (2) exacerbation of subclinical immune responses against antigens expressed in the
cancer and nervous system (onconeuronal antigens) resulting in paraneoplastic neurologic
syndromes.2 There are reports suggesting that these ICI-enhanced paraneoplastic immune
responses can be mediated by autoantibodies (e.g., anti-N-methyl-D-aspartate receptor
[NMDAR] encephalitis) or T cells causing some of the classic paraneoplastic syndromes (e.g.,
anti–Hu-associated encephalitis).3 The study of these complications offers an opportunity to
better understand the immune mechanisms involved in similar neurologic disorders when they
occur without the use of ICIs. In the March 2018 issue of N2, Hottinger et al.4 described a 71-
year-old womanwho developed anti–Hu-associated paraneoplastic encephalitis after the use of 2
ICIs (ipilimumab and nivolumab) to treat her metastatic small cell lung cancer (SCLC). Con-
sidering that this disorder is mediated by T cells against a family of onconeuronal antigens (Hu
proteins), the authors reasoned that natalizumab would block the migration of these T cells into
the brain mitigating the neuronal damage, while not affecting the T cell activity against the
systemic cancer. Indeed, after treatment with natalizumab, the patient had substantial neurologic
improvement and a durable oncologic response. This case suggests that with the increasing use of
ICIs in patients with tumors prone to associate with paraneoplastic immune responses (e.g.,
SCLC), the number of irAE manifesting as paraneoplastic syndromes may increase. Moreover,
the strategy of using natalizumab or similar drugs for T cell–mediated paraneoplastic disorders
deserves further investigation with prospective clinical trials.
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One of the initially recognized potential triggers of autoimmune
encephalitis was the association with tumors, with histologic
types varying according to the immune response (e.g., teratoma
in anti-NMDAR encephalitis or SCLC in GABAb receptor
encephalitis).5 More recently, some of these disorders (anti-
IgLON5, anti-LGI1, and anti-Caspr2) have been found to be
associated with distinct human leukocyte antigen Class II
haplotypes, suggesting an underlying genetic predisposition.6–10
Despite these tumor associations or genetic susceptibility, the
mechanisms that trigger the immune response in many
patients remain unknown. The identification that autoimmune
encephalitis, mainly associated with NMDAR antibodies, can
occur a few weeks after herpes simplex encephalitis (HSE),
suggested the possibility of viruses as triggers of brain auto-
immunity.11 One proposed mechanism is that the viral en-
cephalitis causes a release of neuronal proteins (among them
NMDAR or other cell surface proteins), which in the context
of extensive inflammation leads to an autoimmune response
against the neuronal antigens. This mechanism is supported by
2 findings: (1) the close time-relationship (less than 3months)
between HSE and the subsequent development of autoim-
mune encephalitis and (2) the variety of autoantibodies
identified in these patients, including antibodies targeting the
NMDAR, gamma-aminobutyric acid (GABA)a receptor, and
unknown cell surface antigens.11 Another proposed mecha-
nism is that the immune response post-HSE is triggered by
molecular mimicry. Although molecular homology between
herpes simplex virus 1 (HSV-1) and NMDAR has not been
identified, the study of Salovin et al.12 in the July issue of N2
suggests this possibility. The authors used 2 cohorts of pedi-
atric patients with anti-NMDAR encephalitis without a history
of HSE and age-matched control groups. In each cohort, more
participants with anti-NMDAR encephalitis than controls had
anti-HSV-1 IgG antibodies. The findings were statistically
significant for one of the cohorts and when the cohorts were
combined. In addition to molecular mimicry, the authors
raised several alternative hypotheses, such as virus-induced
alteration of NMDAR outside the CNS, or HSV-1 modulation
of the immune system in a manner that allows inappropriate
recognition of native NMDARs.
The persistent risk of cognitive impairment syndromes inHIV-
infected individuals despite complete suppression of virus
replication with anti-retroviral therapy is a difficult diagnostic
and therapeutic challenge. Cysique et al.13 used 1H-MRS to
assess neuronal and glia brain metabolic markers at baseline
and ;23 months in a cohort of 73 HIV+, virally suppressed
patients in comparison with 35 HIV− controls. The HIV+
group had stably lower N-acetyl aspartate (NAA) levels in
caudate and posterior cingulate cortex (PCC); however, a sub-
groupwith progressive impairment had decreasingNAA levels in
the PCC. Individuals with stable impairment also demonstrated
decreasing frontal whitematter (WM) creatinine, which suggests
impaired cellular energetics. The message is clear: HIV sup-
pression alone is insufficient to fully protect the brain from
coactivated pathways associated with progressive injury. We
need predictive risk markers for brain injury in virally suppressed
HIV+ individuals. The study by Fleischman et al.14 of 66 HIV+
virally suppressed patients showed that plasma neopterin levels
were negatively correlated with hippocampal volumes (by 3T
MRI) and episodic memory. Thus, this well-studied marker of
monocyte/macrophage activation may, like neurofilaments
(NFL), be useful for developing a plasma biomarker panel for
not only assessing risk but also tracking the brain’s response to
persistent, suppressed HIV infection and response to adjunc-
tive neuroprotective therapies.
Several articles in 2018 have touched on serious side effects of
modern immunotherapies used in MS and neuromyelitis optica
spectrum disorders (NMOSDs), 2 of which are highlighted here.
Rituximab, a monoclonal antibody targeting the CD20 antigen on
B lymphocytes, has been increasingly used over the past 15 years
to treat patients with NMOSDs, a severe autoimmune condition
of the CNS, in which the optic nerves, the spinal cord, and the
brainstem are preferentially affected. Rituximab’s clinical efficacy
in reducing relapse frequency and severity is beyond doubt;
however, safety issues also have to be taken into consideration
because the number of patients with long treatment courses is
growing. Marcinno` et al.15 followed up 15 patients with
NMOSDs (10 seropositive for the aquaporin-4 [AQP4] anti-
body) treated repeatedly with rituximab over a median of 70
months (range 17–124 months), 7 patients had a follow-up of
at least 70 months. Median interval between rituximab infu-
sions was 11 (3–36) months. Laboratory assessments com-
prised regular measurements of serum immunoglobulin A, G,
andM levels (median sampling interval 4.9 months). In a subset
of patients, serial AQP4 antibodymeasurements and anti-tetanus
(TET), anti–varizella zoster virus (VZV), and Epstein-Barr
virus nuclear antigen (EBNA) IgG were measured.
Treatment with rituximab caused a significant reduction of
IgA, IgG, and IgM.Hypo-IgG (<7.0 g/L) was detectable in 11/
15 patients (73%) at least once over the treatment course. Of
interest, hypogammaglobulinemia for IgG (hypo-IgG) was
present in 4 patients before initiation of rituximab. Similar
observations were reported for hypo-IgA (<0.7 g/L) in 6/15
(40%), in 2 patients before rituximab, and hypo-IgM (<0.4 g/
L) in 9/15 (60%), in 1 patient before rituximab. Three of 15
patients developed severe hypo-IgG (<4.0 g/L) in at least 1
measurement, whereas severe hypo-IgM (<0.2 g/L) was found
in 2 of 15 patients at least once. The frequency of hypo-IgG,
hypo-IgA, and hypo-IgM increased with longer rituximab
treatment courses. Two patients with severe hypo-IgG had
infectious complications after 8 and 9 years of rituximab
treatment (pneumonia with hand, foot, andmouth disease and
bilateral multifocal pyelonephritis). Anti-TET IgG levels were
below the protection threshold (≤0.1 IU/mL) before ritux-
imab commencement in 4/15 patients (27%). Anti-TET levels
decreased in 10/15 patients during rituximab and fell below the
protection threshold in 1. Moreover, anti-TET IgG levels
during rituximab treatment were significantly lower compared
with healthy controls. Anti-VZV and anti-EBNA IgG de-
creased over time in 8/15 patients and 0/6 controls and 12/15
patients and 1/16 controls, respectively.
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This study is clinically very important despite the small sample
size and the monocenter setting because it shows that severe
hypogammaglobulinemia and reduction of anti-TET pro-
tection may develop under treatment with rituximab in a con-
siderable number of patients with NMOSDs. The authors
correctly recommend monitoring the total and class-specific
IgG levels and the anti-TET IgG before and during rituximab
treatment as a measure to mitigate risks of serious infectious
complications of rituximab, in particular with prolonged
treatment courses of 5 years or more.
Daclizumab, a monoclonal antibody inhibiting interleukin-
2 signaling by blocking interleukin-2 receptor alpha
(CD25) was approved for treatment of relapsing MS in
2016. However, the drug was withdrawn voluntarily from
the market by the manufacturer in March 2018. The Eu-
ropean Medicines Agency also recommended suspension
and recall of the drug subsequent to 12 cases of severe
inflammatory brain disorders including 3 deaths. Luessi
et al.16 performed a thorough and insightful workup of 6 cases
of encephalitis following treatment with daclizumab in Ger-
many and an additional vasculitis case from the United States.
The index case in that report was a 32-year-old man with
a typical clinical and radiographic disease course of relapsing-
remitting MS who had been on disease-modifying treatment
with daclizumab for 8 months when he developed aggressive
behavior, incoherent thoughts, delusions, fluctuating dysar-
thria, and progressive memory loss, all of which are not
regarded as classic symptoms of MS. MRI showed a new jux-
tacortical right frontal lobe lesion; EEG was suggestive of
a moderately severe encephalopathy; CSF analysis revealed
pleocytosis and elevated protein levels; and antibodies to glial
fibrillary acidic protein were detected in CSF and serum.
Treatment with high-dose steroids, plasma exchange, and rit-
uximab lead to partial recovery, albeit with persistent neuro-
psychological deficits. The other 6 cases of serious inflammatory
complications emerging on treatment with daclizumab
comprise CNS vasculitis, inflammatory demyelinating CNS
processes, anti-NMDAR-associated encephalitis, acute dis-
seminated encephalomyelitis, and drug rash with eosino-
philia and systemic symptoms syndrome. Outcome was
partial recovery in some cases, whereas 1 patient had severe
disability requiring foster care. The mechanisms underlying
these and other cases remain speculative and presumably
involve an impaired Treg/natural killer cell balance through
inhibition of regulatory T cells without parallel expansion of
immunoregulatory CD56bright natural killer cells. These cases
are in line with previous reports of secondary autoimmunity
under daclizumab treatment including 2 deaths in the pivotal
clinical trials (autoimmune hepatitis and psoas abscess) and
underscore the necessity for increased vigilance toward rare
side effects of new immunomodulatory drugs both in clinical
trials and after approval.
The recent successful introduction of the anti-CD20 anti-
body, ocrelizumab, in MS therapy has highlighted the role
that B cells play in MS pathogenesis. Besides serving as
a source of antibody-producing plasma cells, B cells can
present antigens to T cells and secrete cytokines that pro-
mote differentiation of either proinflammatory or regulatory
T cells. One important question is whether patterns of B cell
cytokine production or B cell subsets associate with partic-
ular stages of MS. Guerrier et al.17 evaluated proinflammatory
IL-6 and anti-inflammatory IL-10 production in B cells from
patients with radiologically isolated syndrome (RIS), clini-
cally isolated syndrome (CIS), untreated patients with
relapsing-remitting MS (RRMS), and healthy controls. They
discovered that high baseline IL-6/IL-10 ratio in patients
with RIS/CIS is associated with disease activity and that this
cytokine imbalance reflected a decrease in IL-10+ B cells,
without a change in IL-6+ B cells. “Double-negative” (IgD-/
CD27-) memory B cells are a subset that are increased in
systemic lupus erythematosus and Sjo¨gren syndrome and are
associated with increased activity of those autoimmune dis-
eases. Of particular interest, this group observed an over-
representation of double-negative memory B cells in CIS and
RRMS, although there were no alterations in distribution of
other B cell subsets examined in any disease phases. Overall,
their data are exciting and support the concept that there may
be skewing toward certain proinflammatory B cell phenotypes
during the evolution of early MS, a possibility that deserves
further investigation.
Although a majority of patients with MS present in the
relapsing-remitting phase, at least one-half of those patients
subsequently enter a progressive phase, which is characterized
by a steady increase in disability. Unlike for RRMS, currently
there is a lack of effective treatments for secondary progressive
MS (SPMS). Whereas T cells and B cells, the lymphocyte
subsets of the adaptive immune system, are thought to have
a central role in directing inflammation associated with RRMS,
the CNS inflammation in progressive MS is characterized by
activation of resident CNS cells (e.g., microglia) that partici-
pate in innate immunity and promote demyelination and
neurodegeneration. Unfortunately, it is not feasible to monitor
the cellular changes associated with progressive MS by con-
ventional MRI. Thus, Rissanen et al.18 used PET with the
radioligand [11C](R)-PK11195 that binds to a protein
expressed on activated microglia and macrophages, and some
astrocytes, to evaluate WM damage in SPMS. They observed
that higher [11C](R)-PK11195 binding in normal-appearing
WM (NAWM) was associated with higher clinical disability
and reduced WM structural integrity and that increasing age
contributed to greater microglial activation in the NAWM
among patients with MS, but not in healthy controls. These
exciting findings establish how PET can be used to quantitate
microglial activation associated with MS progression and serve
as complementary imaging modality in treatment studies of
progressive MS.
Currently approved medications for treatment of RRMS re-
duce inflammation and promote immune modulation. In
contrast, CNS repair, including remyelination and axonal re-
generation, is a major goal for treatment of progressive MS.
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Leucine-rich repeat and immunoglobulin-like domain-
containing Nogo receptor-interacting protein 1 (LINGO-1)
is an inhibitory transmembrane signaling protein expressed by
neurons and oligodendrocytes, which prevents axonal out-
growth and oligodendrocyte differentiation, restraining mye-
lination. Anti-LINGO antibody, opicinumab (BIIB033), is
being advanced in clinical MS studies for its potential
neuroprotection and capability to promote remyelination.
In 2014, a phase I study demonstrated the safety of opici-
numab in patients with MS and healthy controls,19 and it is
now in clinical trials evaluating its efficacy. Because the
mechanism of action (MOA) of opicinumab is attributed to its
action on neurons and oligodendrocytes, it is important to
distinguish its MOA from approved MS therapies, which
modulate activity of immune cells. In this regard, Ranger
et al.20 demonstrated that LINGO-1 is not expressed by im-
mune cells from human peripheral blood or rat spleen,
LINGO-1 blockade did not affect T cell proliferation or cy-
tokine production, and opicinumab treatment of patients with
MS did not cause significant changes in immune system gene
expression in either blood or CSF. Together, their data provide
further support that anti-LINGO-1 treatment exerts its novel
activity via remyelination and/or neuroprotection, indepen-
dent of immune modulation. If MS clinical trials demonstrate
efficacy, opicinumab will be a welcome addition to the arma-
mentarium of treatments.
Lastly, we want to thank our reviewers. We are able to accept
only a minority of submitted manuscripts and must make
difficult decisions regarding which articles will most benefit
our readers and improve patient care. Your thoughtful
comments regarding experimental research investigations,
the uniqueness of study populations, novel methods and
techniques, studies that are especially educational, or new
strategies for diagnosing and treating neurologic disease are
enormously helpful and highly appreciated. Our gratitude for
your dedication to reviewing forNeurology® Neuroimmunology
& Neuroinflammation cannot be adequately conveyed.
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